Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.
Zachery A SchrammBrian G LerouxAndrea C RadickAlicia S VenturaJared W KleinJeffrey H SametAndrew J SaxonTheresa W KimJudith I TsuiPublished in: Addiction science & clinical practice (2020)
Video DOT delivered through mHealth technology platform offers possibility of improving patients' buprenorphine adherence by providing additional structure and accountability. The TAAB study will provide important preliminary estimates of the impact of this mHealth technology for patients initiating buprenorphine, as well as the feasibility of study procedures, thus paving the way for further research to assess feasibility and generate preliminary data for design of a future Phase III trial. Trial Registration ClinicalTrails.gov, NCT03779997, Registered on December 19, 2018.
Keyphrases
- phase iii
- end stage renal disease
- clinical trial
- open label
- chronic kidney disease
- newly diagnosed
- ejection fraction
- randomized controlled trial
- study protocol
- prognostic factors
- type diabetes
- phase ii
- peritoneal dialysis
- double blind
- patient reported outcomes
- stem cells
- metabolic syndrome
- bone marrow
- mesenchymal stem cells
- electronic health record
- glycemic control